PR Newswire Clinical TrialsOriginal article
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting
Data Readoutpositivesurabgene lomparvovecPositive
AI Analysis
Summary
REGENXBIO presented positive three-year durability data for surabgene lomparvovec showing majority of NPDR patients achieved >2-step DRSS improvement with no vision-threatening events or additional treatment requirements in a one-time gene therapy treatment.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Three-year durability data showed majority of Dose Level 3 participants with NPDR demonstrated >2-step DRSS improvement at 3 years post-treatment with no vision-threatening events and no additional treatment needed for diabetic retinopathy
Importance:7/10
Sentiment:
0.80
gene therapydiabetic retinopathyNPDRdurability datathree-year follow-upclinical conference
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 24, 2026 11:17 PM